Multivolume Magnetic Resonance Imaging (MRI) to assess response to triple-combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) in the lung of patients with Cystic Fibrosis (CF)
F. Pennati (Milano (MI), Italy), I. Borzani (Milano (MI), Italy), E. Nazzari (Milano (MI), Italy), M. Russo (Milano (MI), Italy), G. Bischetti (Milano (MI), Italy), C. Rosazza (Milano (MI), Italy), C. Sciarrabba (Milano (MI), Italy), A. Mariani (Milano (MI), Italy), G. Carrafiello (Milano (MI), Italy), A. Aliverti (Milano (MI), Italy), C. Colombo (Milano (MI), Italy)
Source: International Congress 2022 – Monitoring the effect of therapy with CFTR modulators
Session: Monitoring the effect of therapy with CFTR modulators
Session type: Oral Presentation
Number: 1619
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Pennati (Milano (MI), Italy), I. Borzani (Milano (MI), Italy), E. Nazzari (Milano (MI), Italy), M. Russo (Milano (MI), Italy), G. Bischetti (Milano (MI), Italy), C. Rosazza (Milano (MI), Italy), C. Sciarrabba (Milano (MI), Italy), A. Mariani (Milano (MI), Italy), G. Carrafiello (Milano (MI), Italy), A. Aliverti (Milano (MI), Italy), C. Colombo (Milano (MI), Italy). Multivolume Magnetic Resonance Imaging (MRI) to assess response to triple-combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) in the lung of patients with Cystic Fibrosis (CF). 1619
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|